Showing posts with label FDC. Show all posts
Showing posts with label FDC. Show all posts

Tuesday, September 18, 2018

FDCs in type 2 diabetes can still be used




The Ministry of Health and Family Welfare, Government of India has recently prohibited the manufacture for sale, sale or distribution for human use of 328 fixed dose combinations (FDCs) with immediate effect, including FDCs in diabetes.

All of us have read the Government’s notification on FDCs and it has generated some confusion and also raised several questions as to what is allowed and what is not allowed.

Let us talk about the rationality of use of FDCs in diabetes.  

Type 2 diabetes is a progressive disease, characterized by insulin resistance and β-cell dysfunction. As the disease runs its course, the initial oral hypoglycemic agent (OHA) prescribed may lose its efficacy leading to inadequate glycemic control, which requires sequential addition of a second or even a third drug belonging to a different class of OHAs, to achieve target or desired glycemic control.

Combination therapy administered as separate medications may deter patient from adhering to the prescribed treatment.

Combining two or more OHAs as a single-dose fixed-dose combinations (FDCs) therefore improves treatment adherence by minimizing medication burden to the patient and also reduces costs of treatment, which is a very important consideration, given that out of pocket expenditure on health is amongst the highest in India.

A widely used FDC in diabetes is the combination of glimepiride, metformin and pioglitazone in two strengths: lower strength (7.5 mg) & higher strength (15 mg).

Triple drug combinations reduced A1c to a greater extent than two drugs in a systematic review and meta-analysis of randomized controlled trials, which examined the addition of a third agent after dual therapy failure  in patients inadequately controlled with two agents (predominantly metformin and a sulfonylurea or metformin and a thiazolidinedione),. In trials lasting 52 to 54 weeks, addition of thiazolidinediones, GLP-1 receptor agonists, or SGLT2 inhibitors to metformin and sulfonylurea reduced A1c to a similar extent (Diabetes Obes Metab. 2018 Apr;20(4):985-997).

It is important to note that the Govt. notification also says, “It has also “restricted” the manufacture, sale or distribution of six FDCs“subject to certain conditions”.

The Govt. of India’s notification has recommended the discontinuation of only the FDCs containing lower strength of pioglitazone because of inadequate published international literature, but has allowed the FDC of glimepiride and metformin with pioglitazone in higher strength (15mg).

The notification has not questioned the safety and efficacy of the three molecules. The only issue raised is use of a particular strength of the molecule.

Anti-diabetic triple FDCs containing glimepiride, metformin with high dose pioglitazone are approved by DCGI and all patients can be continued on the existing medication.

In case a patient happens to be on the FDC containing the lower strength of pioglitazone (7.5mg), he should be evaluated again.



Status of FDCs for diabetes

Strength
Status
Glimepiride (1mg/2mg) + Pioglitazone (15mg) + Metformin 500mg (Immediate Release/Sustained Release/ Extended Release) Tablet
Allowed
Pio 7.5 + Met 500/1000
Prohibited
Glimepiride 1/2/3 + Pio 15 + Met 1000
Prohibited
Glimepiride 1mg/ 2mg + Pioglitazone 15mg/ 15mg + Metformin 850mg/ 850mg v
Prohibited
Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 2mg
Prohibited
Metformin 850mg + Pioglitazone 7.5 mg + Glimepiride 1mg
Prohibited
Metformin 500mg/ 500mg + Gliclazide SR 30mg/ 60mg + Pioglitazone 7.5mg/ 7.5mg
Prohibited
Voglibose + Pioglitazone + Metformin
Prohibited
Pioglitazone 30 mg + Metformin 500 mg
Prohibited
Pioglitazone 15 mg + Metformin 850 mg
Prohibited
Metformin + Gliclazide + Pioglitazone + Chromium Polynicotinate
Prohibited
Metformin (sustained release) 500mg + Pioglitazone 15 mg + Glimepride 3mg
Prohibited
Metformin (SR) 500mg + Pioglitazone 5mg
Prohibited

The relevant section of the notification is reproduced as below:

NOTIFICATION

New Delhi, the 7th September, 2018

S.O. 4711(E).—Whereas, the Central Government in exercise of the powers conferred by section 26 A of the Drugs and Cosmetics Act, 1940 (23 of 1940) prohibited the manufacture for sale, sale and distribution for human use of drug fixed dose combination of Glimepiride + Pioglitazone + Metformin vide S.O. number 815 (E) published in the Gazette of India: Extraordinary Part II- Section 3(ii), Dated the 10th March, 2016;

And whereas, in compliance with the directions given by the Supreme Court of India in its judgement dated the 15th December, 2017 in Union of India and Anr. v/s Pfizer Ltd. and Ors. Civil Appeal No. 22972 of 2017 (Arising out of SLP (c) No.7061 of 2017), the matter was examined by Drugs Technical Advisory Board constituted under section 5 of the Drugs and Cosmetics Act, 1940 (23 of 1940) which furnished its report on the 31st July, 2018 in respect of above drug to the Central Government.

And whereas, the Drugs Technical Advisory Board recommended that “FDC ofGlimepiride + Pioglitazone + Metformin may be restricted under section 26A for the following strengths: 1. Glimepiride (1mg/2mg) + Pioglitazone (15mg) + Metformin 500mg (Immediate Release/Sustained Release/ Extended Release) Tablet for "Treatment of type-2 diabetes mellitus (T2DM) when diet, exercise along with monotherapy and dual therapy does not achieve glycaemic target" as this FDC with the said strengths is 'rational' for the defined patient population. Further, the label and all the promotional literature including the package insert shall mention the precautions for individual drugs. Any other strength of FDC of Glimepiride + Pioglitazone + Metformin except above mentioned strengths is not recommended”.

Now, therefore, in supersession of the notification of the Government of India, Ministry of Health and Family Welfare (Department of Health and Family Welfare) published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), vide number S.O. 815 (E) dated the 10th March, 2016 and in exercise of the powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 the Central Government hereby, restricts the manufacture, sale or distribution of the drug Fixed Dose Combination of Glimepiride + Pioglitazone + Metformin subject to the following conditions,-

(i) the manufacture, sale or distribution of the said drug shall be in the strength of Glimepiride (1mg/2mg) + Pioglitazone (15mg) + Metformin 500mg (Immediate Release or Sustained Release or Extended Release) Tablet only;

(ii) the said drug shall be used for treatment of type-2 diabetes mellitus (T2DM) when diet, exercise along with monotherapy and dual therapy does not achieve glycaemic target; and

(iii) in respect of the said drug, the label and all the promotional literature including the package insert shall mention the precautions for individual drugs respectively.

This notification shall come into force with immediate effect.
[F. No. X.11035/53/2014-DFQC (Pt. II)]
SUDHIR KUMAR, Jt. Secy.

Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA


Sunday, March 4, 2018

NPPA Chairman Transfer: We hope the govt. did not succumb to industry pressure?



Dr KK Aggarwal
Recipient of Padma Shri

The chairman of National Pharmaceutical Pricing Authority (NPPA), Drugs Controller General of India (DCGI) have been transferred and Directorate General of Health services (DGHS) has been asked to go on leave.

DCGI was responsible for streamlining all clinical trials and also fought for banning fixed dose combinations (FDCs). NPPA had capped stent prices and that of knee implants. It was now exposing rate variations in disposables and non-NLEM drugs and devices.

Transfers are no doubt a prerogative of the govt., but their timing is inopportune. This move of the govt. may be misunderstood.  We only hope that these transfers were not under the influence of industry pressure.

This would only become clear when Dr S Eswara Reddy, who has been appointed as the new DCGI, and the person who will be appointed NPPA chairman would carry forward work on the issues raised by their predecessors.

What is also surprising is that the NPPA Chairman has been asked to proceed on leave without assigning the work to a chairman-designate making NPPA practically a functionless body as of today.

Let’s revisit the issues that the NPPA Chairman had proactively raised, which probably led to his ouster from this job.

Recent alleged incidents of huge bills for treatment from the relatives of deceased patients in private hospitals in Delhi-NCR have been the cynosure of all eyes and have sparked outrage among the general public. The large amounts have also led to their scrutiny by the regulatory authorities following complaints from the families of the deceased patients.

NPPA is the government regulatory agency, which controls the prices of pharmaceutical drugs and devices in the country. Following the complaints filed by the families, NPPA asked for details of billing from these hospitals and analyzed them as per four categories in a report vide File NO. 27(2)/2017-Div-III/NPPA, GOI, Ministry of Chemicals & Fertilizers, Dept. of Pharmaceuticals, NPPA, dated 20.2.2018, which was put in public domain, as follows:

  • Scheduled formulations based on NLEM 2015 (Schedule 1 of DPCO 2013) and under price control
  • Non-scheduled formulations (not under price control and out of Schedule 1 of DPCO 2013)
  • Consumables not listed as drugs (neither under price control and nor under Schedule 1 of DPCO 2013)
  • Medical devices (neither under price control and nor under Schedule 1 of DPCO 2013)

The breakup of the total bill as per the various components was as follows:






Amount
%
Scheduled formulations
2,84,295.71
4.10%

Non-scheduled formulations

17.79,898.66
25.67%
Non-scheduled devices (IV cannula, catheter, disposable syringes with/without needles)

1,05,525.00
1.52%
Consumables (surgical masks, gloves, etc.)

6,63,175.06
9.56%
Diagnostic services

10,78,792.00
15.56%
Cost of procedures

7.91,912.00
11.42%
Consultation & Medical supervision

8.82,432.00
12.72%
Equipment charges

5.16.771.00
7.45%
Room Rent

8,04,850.00
11.61%
Surgery

27,113.00
0.39%
Total

69,34,764.43
100.00%

Scheduled formulations constituted only 4.10% of the total bill. In contrast, the total cost of non-scheduled formulations was 25.67% implying that mostly non-NLEM drugs (non-scheduled branded medicines), which do not fall under price control, were prescribed, the cost of which were exorbitantly high. Hospitals are dictating the MRPs for institutional bulk purchase resulting in profiteering on drugs and devices. “Industry, in order to get bulk supply orders is in a way ‘forced’ to print higher MRPs as per ‘market requirements”, says the report.

Consumables such as surgical masks, gloves etc. were nearly 10% of the total bill and more than twice the expenditure on scheduled (essential) drugs (4.10%). These consumables are outside the purview of the NPPA and are not “under any kind of price control or monitoring of MRPs since these are not even listed as ‘drugs’ under Drugs & Cosmetics Act”. So, their costs cannot be regulated even in public interest. Patients were being overcharged for consumables.

The cost of diagnostic services was nearly 16% of the total bill. The hospital was also overcharging for tests and investigations as the charges were higher than those provided by other independently run private centers.

About 50% of the total cost is the cost of drugs and devices and diagnostics, which is not included in the ‘estimate’ given by the hospitals to the patients and their families. “The total expenditure on drugs and devices and diagnostics is substantially high (46%) and does not make part of the publicized ‘estimate’ or ‘package’ (in case of implants) by the hospitals in comparison to ‘procedures’ (11.42%), room rent (11.61%) etc. which are the more visible components.”

In all this, the doctor consultation and medical supervision charges come out to be a meager 12.72%.

What this report reveals is that it is the hospitals, which mainly benefit from the inflated MRPs and the profits wherefrom and not the manufacturers of the drugs and devices and neither the doctors, in contrast to what is popularly perceived.

But indirectly, doctors are responsible for it, for not raising a voice against it. If they are aware that this is happening, they need to protest against such practices. MCI Ethics Regulation 6.3 clearly says that it is our duty to see that the patient is not exploited either by us or through us. 

6.3 Running an open shop (Dispensing of Drugs and Appliances by Physicians): - A physician should not run an open shop for sale of medicine for dispensing prescriptions prescribed by doctors other than himself or for sale of medical or surgical appliances. It is not unethical for a physician to prescribe or supply drugs, remedies or appliances as long as there is no exploitation of the patient. Drugs prescribed by a physician or brought from the market for a patient should explicitly state the proprietary formulae as well as generic name of the drug.
The judgement of the Supreme Court in the matter of Samira Kohli vs Dr. Prabha Manchanda & Anr on 16 January, 2008 also talks about the same as below.

“28. But unfortunately not all doctors in government hospitals are paragons of service, nor fortunately, all private hospitals/doctors are commercial minded. There are many a doctor in government hospitals who do not care about patients and unscrupulously insist upon 'unofficial' payment for free treatment or insist upon private consultations.

On the other hand, many private hospitals and Doctors give the best of treatment without exploitation, at a reasonable cost, charging a fee, which is reasonable recompense for the service rendered.

Of course, some doctors, both in private practice or in government service, look at patients not as persons who should be relieved from pain and suffering by prompt and proper treatment at an affordable cost, but as potential income-providers/ customers who can be exploited by prolonged or radical diagnostic and treatment procedures. It is this minority who bring a bad name to the entire profession.”

The time has come for the self-regulation. If the hospital industry does not self regulate, then the govt. will do so, which will be not without adding penal provisions for such practices.